Format

Send to

Choose Destination
Pulm Pharmacol Ther. 2015 Dec;35:8-16. doi: 10.1016/j.pupt.2015.09.007. Epub 2015 Sep 21.

Exploring the monocrotaline animal model for the study of pulmonary arterial hypertension: A network approach.

Author information

1
QOPNA, Department of Chemistry, University of Aveiro, Aveiro, Portugal; Department of Physiology and Cardiothoracic Surgery, Faculty of Medicine, University of Porto, Porto, Portugal.
2
QOPNA, Department of Chemistry, University of Aveiro, Aveiro, Portugal; iBiMED, Institute for Biomedical Research, University of Aveiro, Aveiro, Portugal.
3
QOPNA, Department of Chemistry, University of Aveiro, Aveiro, Portugal. Electronic address: ritaferreira@ua.pt.
4
Department of Physiology and Cardiothoracic Surgery, Faculty of Medicine, University of Porto, Porto, Portugal. Electronic address: henriques.coelho@gmail.com.

Abstract

Pulmonary arterial hypertension (PAH) is responsible for the premature death mainly because of progressive and severe heart failure. This disease is characterized by increased pulmonary vascular tone, inflammatory cell infiltration, vascular remodeling and occlusion of vessels with thrombi, frequently leading to right heart failure. Aiming to better comprehend the complexity of PAH and find novel therapeutic strategies or improve the existing ones, a variety of preclinical models have emerged. Although there is no ideal preclinical model of PAH currently available, animal models have been used to assist in the identification of the molecular pathways underlying PAH development and progression, and in the identification of novel therapeutics. Among preclinical models of PAH, monocrotaline (MCT) animal model offers the advantage of mimic several key aspects of human PAH, including vascular remodeling, proliferation of smooth muscle cells, endothelial dysfunction, upregulation of inflammatory cytokines, and right ventricle failure, requiring a single drug injection. This review summarizes the advantages and limitations of MCT animal model to the study of the molecular mechanisms underlying PAH pathogenesis, envisioning to improve the diagnosis and management of this complex disease.

KEYWORDS:

Inflammation; Preclinical models; Pulmonary arterial hypertension; Vascular remodeling

PMID:
26403584
DOI:
10.1016/j.pupt.2015.09.007
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center